Pelthos Therapeutics Inc. (PTHS)
NYSE: PTHSHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
PTHS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $25.08M
- EPS (TTM)
- -$23.86
- Dividend yield
- None
- 52-week range
- 6.02 – 31.62
- Day range
- 6.38 – 7.21
- Volume / Avg
- 63.96K / 54.38K
- Beta
- —
- Shares outstanding
- 3.93M
52-week range
PTHS stock today
Shares of Pelthos Therapeutics (PTHS) finished lower on Nov 20 at $6.38, a drop of 8.73% or $0.61 per share, versus the S&P 500's 3.70% decline. Shares are 79.8% below their 52-week high of $31.62, set on Dec 31, 2025 and 6.0% above the 52-week low of $6.02, near the bottom of the past year's range. PTHS is down 79.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 74.9%.
Pelthos Therapeutics has posted a net loss over the last twelve months (EPS of -$23.86), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Pelthos Therapeutics
Company profilePelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Scott M. Plesha
- Headquarters
- Durham, NC
- Employees
- 92
- IPO year
- 2024
- Website
- pelthos.com
Financial highlights
Full financialsIn fiscal 2025, Pelthos Therapeutics generated $16.8 million in revenue, up 0.0% from fiscal 2024. Pelthos Therapeutics reported a net loss of $43.3 million, compared with a loss of $8.0 million a year earlier. Gross margin was 76.3% and operating margin -193.1%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Revenue | $16.80M | $0 | — | — |
| Growth | — | — | — | — |
| Net income | $-43.32M | $-7.96M | $-7.38M | $-2.46M |
| EPS (diluted) | $-23.04 | $-14.27 | $-5.78 | — |
Analyst forecast
ForecastConsensus (7 analysts)
strong_buy
Avg. price target
$53.14+732.92%
- Strong buy 1
- Buy 6
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-2.04 vs $-2.83
- Surprise
- +27.92%
PTHS news
All PTHS news- Pelthos (PTHS) Q3 2026 Earnings Call TranscriptNasdaq
- Pelthos Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire
- Weekly Buzz: RDY, LUPIN, SUNPHARMA Score FDA Wins; AGIO, RARE Slash Jobs; CVS Plots SplitNasdaqABT, AGIO, BEAT, BIOA
- Pelthos Therapeutics to Combine with Castle Creek Biosciences, Creating Transformative Biotechnology Company Focused on Serious Diseases that Affect the SkinGlobeNewswire
Pelthos Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| INMBINmune Bio Inc. | 0.827 | -7.50% | $25.60M | vs PTHS |
| SAENGenenta Science S.p.A. ADR | 0.5074 | -9.39% | $24.47M | vs PTHS |
| LONALeonaBio Inc. | 2.02 | -17.89% | $26.41M | vs PTHS |
| EXOZeXoZymes Inc. | 2.91 | -14.05% | $27.42M | vs PTHS |
| MGXMetagenomi Therapeutics Inc. | 0.565 | -7.95% | $21.36M | vs PTHS |
| CVMCel-Sci Corporation | 1.21 | -17.69% | $21.28M | vs PTHS |
| EVAXEvaxion A/S ADR | 2.25 | +10.84% | $20.75M | vs PTHS |
| KLRSKalaris Therapeutics Inc. | 1.28 | -5.19% | $30.47M | vs PTHS |
Indexes, lists and sector
Pelthos Therapeutics stock FAQ
What is Pelthos Therapeutics's stock price today?
PTHS last traded at $6.38 as of Nov 20, 4:00 PM EST, down 8.73% on the day. Prices are delayed at least 15 minutes.
Does Pelthos Therapeutics pay a dividend?
No. Pelthos Therapeutics does not currently pay a regular cash dividend.
Who is Pelthos Therapeutics's CEO?
Mr. Scott M. Plesha is the chief executive officer of Pelthos Therapeutics Inc., which has about 92 employees.
Has PTHS ever split its stock?
Yes. The most recent PTHS stock split was a 1-for-10 split on Jul 2, 2025.
What is the PTHS 52-week high?
The 52-week high for PTHS is $31.62 and the 52-week low is $6.02. The stock is currently 79.8% below its high.